Normal values for neurone specific enolase in amniotic fluid have been found to follow a non gaussian distribution with a 1-99 centile range of 1·10-4·32 ",gIL. Neurone specific enolase levels have been shown to be raised in the amniotic fluid of pregnancies complicated by anencephaly, although not those complicated by open spina bifida. Neurone specific enolase measured by radioimmunoassay is capable of totally discriminating between normal pregnancies and those complicated by anencephaly. The study demonstrates the possible value of investigating other neuronal proteins which may find value as adjuncts to amniotic fluid Alpha fetoprotein levels in the prenatal diagnosis of Neural Tube Defects.
The measurement of alpha fetoprotein (AFP) in amniotic fluid has proved to be an effective biochemical tool in the prenatal detection of neural tube defects (NTD). However, amniotic fluid AFP does not completely discriminate between a normal foetal population and a population affected by NTD. The need for follow-up procedures to confirm the presence or absence of an affected foetus is now both accepted and desirable. This need has resulted in a number of biochemical tests being suggested as adjuncts to the measurement of amniotic fluid AFP, but of the many tests suggested only acetylcholinesterase and alpha 2 macroglobulin measurements effectively separate the normal and abnormal populations. 2 • 3 Alpha 2 macroglobulin measurements cannot be recommended for routine use because of the very high susceptibility to contamination of amniotic fluid with foetal or maternal blood containing large quantities of alpha 2 macroglobulin. In practice acetylcholinesterase isoenzyme electrophoresis" is both time consuming and the interpretation very much operator dependant, whilst the use of the differential inhibitor technique'' suffers from specificity problems especially with blood stained samples.
In an attempt to study other potential neural markers, we have examined a panel of amniotic fluid samples from pregnancies with normal outcome and from pregnancies complicated by neural tube defects using a radioimmunoassay for neurone specific enolase (NSE).
Neurone specific enolase is a neuronal form of the dimeric glycolyticenzyme enolase, which was first found in extracts of brain tissue and later shown to be present in APUD cells and neurones of the diffuse neuroendocrine system, but not in other peripheral cells. In the central nervous system this specific enzyme is mainly localised in neuronal cells as y y and a y isoenzymes of enolase.v"
In pregnancies complicated by anencephaly and open spina bifida (OSB) there is increased exposure of neural tissue to the amniotic fluid. Exposed or damaged neurones may then be in a position to leak NSE into the amniotic fluid thereby raising the levels of NSE in pregnancies complicated by these disorders.
Methods
Amniotic fluid samples from women identified by our NTD maternal serum AFP screening programme as being of a high risk of carrying an NTD affected foetus, were collected by transabdominal amniocentesis during the second trimester of the pregnancy. The amniotic fluid samples were centrifuged on receipt in the laboratory and stored in aliquots at -20"C prior to analysis. Data on pregnancy outcome were recorded after termination or after term delivery. The amniotic fluids were
Results

ASS A Y PRECISION
The within assay and between assay precision profiles for the NSE assay are shown in Fig. I . This clearly shows acceptable assay performance (within assay CV of less than 10%) over a range of 1·5 to at least 100 ",giL.
ASSAY SENSITIVITY
The detection limit as defined by three times the standard deviation at zero dose was shown over four assays to vary from O·6. . . . ()·9 ",giL with a mean of 0·75 ",giL. The method used for measuring NSE was developed for use with serum or plasma samples. In order to run amniotic fluid samples. which have significantly lower protein content. it was necessary to check assay recovery in serum. calibrant and amniotic fluid samples. to establish the absence of a matrix effect in the assay. Table 1 shows the results of the recovery of a 200 ",giL standard added to the normal sera, amniotic fluid from a normal pregnancy. amniotic fluid from an abnormal pregnancy and finally, to assay buffer. The data clearly show good recovery in all situations. Figure 2 Measurements of NSE were performed in duplicate using a double antibody radioimmunoassay method (Pharmacia Ltd. Pharmacia House, Midsummer Boulevard. Milton Keynes, UK) according to the manufacturer's protocol. Bound radioactivity was counted using a NE 1600 multi-head gamma counter (Nuclear Enterprise Ltd, Sighthill, Edinburgh. Scotland) and the counts processed using the WHO Mass Action curve. fitting routine and an Apple IIe computer. data obtained by diluting a high amniotic fluid sample in assay buffer and shows a linear dilution curve. Clearly the assay does not suffer adversely from matrix effects in the context of measuring amniotic fluid samples. Table 2 shows the data obtained from the analysis of 62 amniotic fluid samples collected Neurone specific enolase 87 between weeks 16 and 23 from pregnancies with normal outcome. The data at each gestational week would seem to indicate no variation of NSE with gestational age, although the lower values at 22 and 23 weeks need more clarification because of the small number of samples tested at this time. The mean (±2SD) levels for the grouped data, after log transformation, was found to be 2·25 (0'88-3·63) ",gIL and the median value was 2·40 ",gIL. The data showed a non gaussian distribution (Figure 3) skewed to higher levels. The 1st and 99th centile range was H0-4·32 ",gIL. Amniotic fluid samples from 51 cases of abnormal pregnancy were analysed for NSE. The data for each group are summarised in Table 3 . The use of the non parametric Mann-Whitney 'U' test applied to the normal and abnormal groups showed that whilst the mean level for the OSB group was higher than the normal group, this was not statistically significant. The NSE levels of the anencephalic group, however, were statistically significantly higher than the normal population. Figure 4 shows the clear separation of anencephalic pregnancies from both normal and OSB pregnancies, although no such discrimination can be shown for the OSB group against the normal population.
REFERENCE RANGE
Conclusions
The data presented clearly show a significant increase in amniotic fluid NSE levels in pregnancies complicated by anencephaly and that NSE could be used to identify affected cases since there is no overlap between the normal and affected populations. However, NSE from open spina bifida cases showed a close overlap with the normal population making it impossible to identify affected pregnancies using NSE.
The findings of this study are similar to those of the short study of Sorensen et al. 9 who found raised NSE levels in the amniotic fluid and maternal serum of 50% (8115 cases) of pregnancies affected by NTD, although no information was presented on the type of NTD.
The increased levels of NSE in anencephaly can probably be explained by the larger area of neurones exposed to the amniotic fluid in such conditions, compared to that in open spina bifida where the degree of exposure is much less.
. The prenatal diagnosis of anencephaly under routine conditions is usually made either by ultrasound or by the observation of raised maternal serum AFP and confirmed by the presence of raised amniotic fluid AFP. In our hands maternal serum AFP screening detects 97% of cases of anencephaly!" and it is unlikely that measurement of NSE on a routine basis would improve the situation bearing in mind discrimination for open spina bifida is poor. However, the increased levels of this neuronal protein we have found in anencephaly will encourage us to look further at other neuronal proteins which may find their way into the amniotic fluid in NTD affected pregnancies.
